Article

A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy

2015-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dc4db968-a8dc-5625-a5c4-179eaa3991a3
DOI: 10.1186/1750-1172-10-s1-p8
PMCID: PMC4641994

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathyDOI 10.1186/1750-1172-10-s1-p8Read

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin AmyloidosisSemantic proximity Read

Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotidesSemantic proximity Read

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatmentsSemantic proximity Read

RNA Targeting and Gene Editing Strategies for Transthyretin AmyloidosisSemantic proximity Read

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathySemantic proximity Read

Transthyretin Amyloid Cardiomyopathy–2025 Update: Current Diagnostic Approaches and Emerging Therapeutic OptionsSemantic proximity Read

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).Semantic proximity Read

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trialsSemantic proximity Read

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read

Emerging Pharmacological Strategies for Cardiac Amyloidosis: A Qualitative Analysis of Interventional Clinical Trials Registered on ClinicalTrials.govSemantic proximity Read